Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Biopharma ( (TSE:QNTM) ) has issued an update.
On March 23, 2026, Quantum BioPharma announced that a double-blind, randomized, placebo-controlled crossover clinical trial of its dietary supplement Unbuzzd has been published in the peer-reviewed World Journal of Pharmaceutical and Medical Research. The study, conducted in healthy adults who first reached a blood alcohol concentration of 0.07% to 0.11%, found that Unbuzzd significantly accelerated alcohol metabolism, reducing blood alcohol levels more than 40% faster within 30 minutes on average than placebo while improving alertness and cardiovascular stability.
Participants using Unbuzzd reported statistically significant reductions in symptoms of intoxication, perceived impairment, mental fatigue, and hangover, including a 67% reduction in headache severity at four hours versus placebo, with no reported adverse side effects. The publication provides third-party validation for Unbuzzd, potentially strengthening Quantum BioPharma’s positioning in the alcohol-misuse and wellness markets and adding credibility to a royalty- and equity-based income stream tied to Unbuzzd Wellness Inc., which markets the product directly to consumers.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a Toronto-based biopharmaceutical company focused on developing innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through subsidiary Lucid Psycheceuticals, it is advancing Lucid-MS, a patented new chemical entity that has shown an ability to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company invented the alcohol-related product Unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.86% stake as of September 30, 2025 and a tiered royalty on product sales. Quantum BioPharma also holds approximately C$130 million in tax loss carryforwards for potential future use and maintains a portfolio of secured loans via its FSD Strategic Investments Inc. subsidiary, providing a diversified financial base alongside its drug development pipeline.
YTD Price Performance: -70.38%
Average Trading Volume: 9,040
Technical Sentiment Signal: Sell
Current Market Cap: C$12.81M
Find detailed analytics on QNTM stock on TipRanks’ Stock Analysis page.